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COPD phenotypes and history of pneumonia can impact on exacerbation of COPD
in Korea. We need to investigate further prospective studies to reach the concrete
conclusion.
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REAL WORLD EFFECTIVENESS AND RELATIVE EFFECTIVENESS OF
OMALIZUMAB. AN HISTORIC-PROSPECTIVE DESIGN STUDY
Grimaldi-Bensouda L1, Abenhaim L2
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OBJECTIVES: Omalizumab has been shown to decrease the risk of hospitalisation
or emergency visits in patients with uncontrolled severe allergic asthma as com-
pared to placebo. This longitudinal study observed the conditions under which
omalizumab is prescribed in real-life settings; and assessed whether its use, as an
add-on therapy alongside standard treatments, decreases the risk of severe asth-
matic exacerbations. METHODS: A cohort of adult patients with uncontrolled se-
vere asthma despite optimal treatment with inhaled and oral corticosteroids and a
long-acting beta2-agonist, but no treatment with omalizumab upon entry, was
assembled. Risk of hospitalisation and/or emergency room visits for asthma exac-
erbation was assessed using the Andersen-Gill extension of the Cox model for
repeated events controlling for age, gender, smoking history, body mass index,
gastro-oesophageal reflux, allergic status, allergic rhinitis, treatment, and hospi-
talisation or emergency room visits for asthma in the 2 months prior to omali-
zumab treatment. RESULTS: Overall, 163 physicians recruited 767 patients, of
whom 374 took omalizumab at least once (mean observation period: 20.4 months).
Omalizumab use was associated with an adjusted relative risk of hospitalisation
and/or emergency room visits for asthma of 0.57 (95% confidence interval: 0.43-
0.78). In omalizumab users, the adjusted relative risk of hospitalisation and/or
emergency room visits for asthma during omalizumab treatment versus non-treat-
ment periods was 0.40 (95% confidence interval: 0.28-0.58). CONCLUSIONS:Add-on
omalizumab significantly decreases the risk of hospitalisation/emergency room
visits in patients with uncontrolled severe asthma in the real-life practice.
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COMPARATIVE EFFICACY OF ACLIDINIUM BROMIDE 400 MCG BID VERSUS
TIOTROPIUM 18 MCG AND 5 MCG QD AS MAINTENANCE BRONCHODILATOR
TREATMENT TO RELIEVE SYMPTOMS IN ADULT PATIENTS WITH CHRONIC
OBSTRUCTIVE PULMONARY DISEASE (COPD): A NETWORK META-ANALYSIS
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G1
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OBJECTIVES: To estimate the relative efficacy of a new long-acting muscarinic
antagonist (LAMA), aclidinium bromide 400 g BID (AB400), to tiotropium bromide
18 g (TIO18) and 5 g (TIO5) QD in patients with COPD. METHODS: A systematic
literature search using a predefined strategy in MEDLINE©, EMBASE© and the Co-
chrane Library identified 21 unique placebo-controlled RCTs: TIO18 (16 trials), TIO5
(3 trials) and AB400 (2 trials). Outcomes were change from baseline (CFB) in lung
function (trough FEV1), disease-specific health status by St. George’s Respiratory
Questionnaire (SGRQ) total score, and breathlessness by Transition Dyspnea Index
(TDI) focal score, at 12 and 24 weeks. All trials were analysed simultaneously using
a Bayesian network meta-analysis and relative treatment effects between all reg-
imens were obtained. Meta-regression techniques were included to investigate
dissimilarities in study design and patient characteristics across trials. RESULTS:
In line with the pivotal trials, AB400 was shown to be more efficacious than placebo
on all evaluated endpoints. AB400 showed comparable but numerically greater
improvements at 12 weeks compared to TIO18 in trough FEV1 [difference in CFB
(95% Credible Interval) 0.001L (-0.03,0.03)], SGRQ total score [-0.85 (-3.41,1.75)] and
TDI focal score [0.06 (-0.41,0.52)]. Similar but numerically greater differences were
also seen for AB400 versus TIO18 at 24 weeks in trough FEV1 [0.02L (-0.02,0.08)],
SGRQ total score [-1.84 (-4.21,0.51)] and TDI focal score [0.10 (-0.53,0.73)]. Addition-
ally, AB400 showed similar improvements on these same endpoints versus TIO5
(where data was available). Meta-regression analyses, correcting for differences in
treatment patterns (concurrent ICS, LABA treatment) and COPD severity (baseline
FEV1 percent predicted) across the trials, showed comparable findings as the base
case analysis. CONCLUSIONS: This meta-analysis suggests that maintenance
treatment with aclidinium 400 g BID results in comparable improvements in lung
function, health status, and breathlessness as tiotropium 18 g and 5 g QD in
COPD patients.
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DUAL BRONCHODILATION WITH INDACATEROL AND TIOTROPIUM IN
COMBINATION VERSUS TRIPLE THERAPY, FIXED-DOSE COMBINATIONS, AND
MONOTHERAPY IN COPD – A NETWORK META-ANALYSIS OF FEV1
Kraemer M1, Ellis A2, Baldwin M3, Jansen JP2, Capkun-Niggli G1, Cope S2
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OBJECTIVES: To evaluate the relative efficacy of indacaterol 150g  tiotropium
18g (IND/TIO) versus triple therapies (i.e. tiotropium plus a fixed-dose combina-
tion [FDC] of a long-acting beta2-agonist [LABA] and inhaled corticosteroid [ICS]), a
LABA/ICS FDC alone, and monotherapies, including indacaterol, tiotropium, acli-
dinium, salmeterol, formoterol, and placebo in patients with moderate to severe
chronic obstructive pulmonary disease (COPD) in terms of trough FEV1 at 12 weeks.
METHODS: Several of the treatments to be compared include ICS as part of the
study treatment. Therefore the evidence base was restricted to RCTs not allowing
for concomitant ICS use (for Novartis studies subgroup data for non-ICS users were
included). For this population 23 RCTs were identified based on a systematic liter-
ature review, which were analysed simultaneously using a Bayesian network
meta-analysis. Treatment-by-covariate interactions were included for the propor-
tion of current-smokers to improve similarity of the trials. RESULTS: IND/TIO re-
sulted in a higher change from baseline (CFB) in FEV1 by 0.24L (95%CrI: 0.20, 0.27)
versus placebo at 12 weeks. IND/TIO is likely to be favourable versus salmeterol/
fluticasone 50/500g tiotropium 18g [difference 0.03L (95%CrI: -0.01, 0.07); prob-
ability better: 94%] and comparable to formoterol/budesonide 9/320g  tiotro-
pium 18g [difference 0.02L (95%CrI: -0.02, 0.06); probability better: 80%]. IND/TIO
has a larger CFB than the FDCs alone with an advantage of 0.07L (95%CrI: 0.03, 0.12)
to 0.09L (95%CrI: 0.04, 0.15). IND/TIO also has a higher CFB than the monotherapies
assessed. Out of the 13 regimens evaluated, there is a 77% probability that IND/TIO
is the most efficacious treatment in terms of CFB in FEV1. Results were not sensitive
to adjustment for smokers or to the exclusion of RCTs with concomitant anticho-
linergics or an exacerbation history. CONCLUSIONS: IND/TIO is expected be com-
parable to triple therapies and more efficacious than FDCs and monotherapies in
terms of FEV1 at 12 weeks.
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OBJECTIVES: To compare the prevalence of selected medical conditions in Russia
as estimated using the National Health and Wellness Survey (NHWS) with those
from the medical literature. METHODS: This study used data from the 2011 Russia
NHWS, a cross-sectional survey administered to 10,039 adults living in large Rus-
sian cities recruited through both online and offline methods. All data were self-
reported. Weighted prevalence was estimated through self-report and validated
scales embedded in the questionnaire. Conditions included depression, restless
legs syndrome, and sleep difficulties, among others. Gender differences were also
assessed. NHWS estimates were compared with prevalence estimates taken from
published studies. RESULTS: Twelve-month prevalence estimates of depression
according to self-report were 20% in men and 25% in women, and depression of
moderate or greater severity was identified through Patient Health Questionnaire
(PHQ-9) in 17% of men and 21% of women, both slightly higher than the approxi-
mately 10% and 20% estimates of clinically significant depression in men and
women, respectively, reported by Akarachkova and Vershinina (2010). In NHWS,
restless leg syndrome was reported by 6% and 10% of men and women respectively,
and found to affect 8% of men and 10% of women by Romanova (2008). Difficulty
falling asleep was estimated at 25% of men and 32% of women in NHWS, and 30%
of men and 28% of women (Romanova, 2008). Prevalence for all conditions among
urban Russian adults was much lower across conditions when limited to patients
reporting a diagnosis confirmed by a doctor. CONCLUSIONS: Prevalence estimates
and gender differences calculated from NHWS Russia data were generally similar
to those taken from previous literature, providing initial evidence for its use in
estimating prevalence of disease in urban Russia. Reports of experiencing a condi-
tion were much more common than reports of confirmed diagnosis, suggesting
substantial unmet medical need.
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PATTERNS OF INTRANASAL CORTICOSTEROID USE AMONG INDIVIDUALS
DIAGNOSED WITH ALLERGIC RHINITIS: EVIDENCE FROM A LARGE CLAIMS
DATABASE
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OBJECTIVES: Examine patient characteristics and patterns of intranasal corticoste-
roid (INS) use among individuals diagnosed with allergic rhinitis (AR) from a large,
US retrospective claims database.METHODS: The i3 Invision™ Data Mart was used
from January 1, 2006 through December 31, 2010. AR patients aged 12 years were
included if they received an aqueous INS formulation (with first such date identi-
fied as index date) and had continuous insurance coverage from 6 months before
through 24 months after index date. Patients diagnosed with chronic rhinitis or
nasal polyps were excluded. Data are descriptive in nature. RESULTS: The sample
consisted of 163,473 individuals with a mean age of 41 years (SD15), 59% female,
and 55% residing in the southern US. Patients were most commonly prescribed
generic fluticasone propionate (44%), mometasone (34%), or triamcinolone (10%)
and had a high degree of related comorbidities, including sinusitis (40%), asthma
(15%), and otitis media (12%). Treatment patterns during the first year after index
date: a mean of 2.1 INS prescriptions were filled (median1.0; SD1.8), adherence
as measured by the medication possession ratio averaged 18% (median8; SD16),
and persistence averaged 135 days (median30; SD134). Furthermore, 7% of pa-
tients switched INS products during their first year of use, with 5% of patients who
initially received generic INS switching to a branded INS product. CONCLUSIONS:
Although INSs are considered the gold standard for symptomatic treatment of AR,
this examination of a large US claims database demonstrated that patients with AR
who filled at least 1 aqueous INS prescription generally did not use their INS for an
extended period of time.
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BURDEN OF EXACERBATIONS IN PATIENTS WITH COPD IN THE NETHERLANDS:
A REAL-LIFE STUDY
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OBJECTIVES: To determine recurrent (infective) exacerbations (AECOPD) and
health care utilization among patients with moderate to very severe COPD.
METHODS: Data for this study was obtained from the PHARMO Record Linkage
System (RLS), which includes drug dispensing records from pharmacies, hospital-
ization records and detailed information from general practitioners. Patients with
moderate to very severe COPD (GOLD II-III-IV) and a moderate or severe AECOPD
between 2000 and 2010 were included in the study. Moderate and severe AECOPD
were defined by drug use and hospitalizations respectively. Date of first AECOPD
after first GOLD classification-test was defined as cohort entry. Study patients were
followed from cohort entry to end of registration in PHARMO RLS, death, or end of
study period, whichever occurred first. During follow-up, all recurrent AECOPDs
were counted and characterized by type of AECOPD and health care utilization.
RESULTS:Of 886 patients included in the study, 56% was male and mean (SD) age
was 66 (11) years. The proportion of patients with GOLD II, III and IV was 52%, 34%
and 14% respectively. At cohort entry, 747 patients (84%) had a moderate AECOPD
and 139 (16%) had a severe AECOPD. The overall exacerbation recurrence rate per
person year (PY) was 0.9. When stratifying by GOLD stage at cohort entry, this rate
increased from 0.6 for patients with GOLD II to 1.1 for GOLD III patients and 1.3 for
GOLD IV patients. The rate of severe exacerbations was 0.1 for patients with GOLD
II and III and 0.2 for patients with GOLD IV. Mean hospital stay for severe exacer-
bations was 12 (11) days and 75% were infectious. Moderate exacerbations were
mostly treated with tetracyclines (46%), followed by penicillins (34%).
CONCLUSIONS: This study provides a comprehensive overview of recurrent AE-
COPD among patients with moderate to very severe COPD, but also emphasizes the
need for more research in infective AECOPD.
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ALLERGIES: DISTRIBUTION AND PERCEPTION IN THE GERMAN GENERAL
POPULATION
Schaefer I1, Franzke N1, Stadler R2, Augustin M3
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OBJECTIVES: To obtain population based data on the prevalence of allergies and to
provide insight into allergy care and perceptions. METHODS: A random represen-
tative sample of the German population (18 years) was recruited for a telephone
survey in 2012. Descriptive data were stratified by criteria relevant for health-
service research as age, sex, geographical region insurance status. RESULTS: For
51% of the n1.004 respondents the topic “allergy” was personally relevant. One
third of all respondents (33%) rated a physician-diagnosed allergy. Prevalence was
higher in women (39%) than in men (27%) and in persons with higher educational
level (39% vs. 33% lowest level). The most common allergen (43%) was pollen; 15%
reported to have contact dermatitis (women 21%, men 5%). The majority of allergic
persons (53%) felt (highly) burdened and 48% were limited in their daily activities
due to symptoms. 70% have ever seen a physician or other therapist for their
allergy (East: 62%, West 72%); GPs (45%) and dermatologists (41%) were consulted
mainly. Self-medication was frequent among allergic persons (58%); it was most
prevalent in the highest income and education groups as well as in West Germany.
Medical treatment of acute symptoms was reported by 21% of the respondents.
Regarding allergy perception, 39% appraised allergies as “easily treatable”; this
opinion was more prevalent in women and in privately insured persons. In an open
question on potential allergy triggers environmental factors were mentioned most
often (26%), chemical agents. CONCLUSIONS: About one-third of the German gen-
eral adult population is affected by allergies and constricted by acute symptoms.
There is evidence for need of improvement concerning awareness and appraisal of
allergies - which are not distributed evenly over social groups. In particular, there is
a gap of using adequate medical treatment of acute symptoms.
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AN ANALYSIS OF REPORTED PNEUMONIA DEATHS IN MALAYSIA
Azmi S, Abdul Aziz SH, Goh A
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OBJECTIVES: It is estimated that there are 25 million cases of pneumonia world-
wide with 63,500 deaths from the disease annually. Streptococcus pneumoniae
(S.pneumonia) is one of the main pathogens that cause pneumonia. Apart from
S.pneumonia, some other common pathogens include Haemophilus influenzae, Staph-
ylococcus aureus and Klebsiella pneumoniae. However, pneumonia data from South
East Asia is lacking. According to the Department of Statistics Malaysia, pneumo-
nia is one of the top five causes of death in Malaysia. This study sought to describe
pneumonia mortality in Malaysia using death statistics from the Department of
Statistics Malaysia. METHODS: This study used death data from 2004 to 2008 ob-
tained from Department of Statistics Malaysia. For the purpose of analysis, medi-
cally certified deaths that were due to pneumonia were analysed by age group.
Pneumonia death rate was calculated against the population age cohorts for each
year. Rates were reported in deaths per 100,000 population. RESULTS: The average
crude mortality rate in Malaysia for the period 2004 to 2008 ranged from 440.4 to
454.0 per 100,000 population. However, deaths attributed to pneumonia showed an
increasing trend from 11.9 (2004), 12.9 (2005), 13.8 (2006), 15.6 (2007) and 19.3 (2008)
per 100,000 population. CONCLUSIONS: Deaths due to pneumonia over the period
2004 to 2008 have shown an increase even though the crude death rate has been
stable during that time. Further analysis to determine pathogens and aetiology of
the pneumonia deaths is warranted.
RESPIRATORY-RELATED DISORDERS - Cost Studies
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THE SHORT-TERM ECONOMIC IMPACT OF THREE CHILDHOOD PREVENTIVE
HEALTH PROGRAMS IN ISRAEL
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OBJECTIVES: To estimated the budget impacts of immunization against pneumo-
coccal disease (PD) and human papillomavirus (HPV), and of prophylaxis against
severe respiratory syncytial virus (RSV) disease, in Israel. METHODS: Incidence-
based models compared the annual budget impact, from the Israeli health care
system perspective, of the PD and RSV programs. Because HPV disease is slow
developing, cumulative five-year disease costs were instead modelled for this pro-
gram. Model inputs were from published literature. Outputs included total pro-
gram cost, disease costs and disease cost offsets, in 2012 Israeli New Shekels (NIS).
RESULTS: A 13-valent pneumococcal conjugate vaccine (PCV13) vaccination pro-
gram, covering 175,428 infants, prevented approximately 78 cases of invasive dis-
ease, 218 of pneumococcal pneumonia and 225 of pneumococcal otitis media. Im-
munization against HPV in a year’s cohort of 66,185 twelve-year old girls prevented
approximately 321 cases of cervical intraepithelial neoplasia and 48 cases of genital
warts over five years. RSV prophylaxis in 2,266 high-risk infants prevented approx-
imately 138 hospitalizations for severe RSV disease. Total disease costs in year one
of the model, without the programs, were 7,250,461 NIS (PD) and 17,988,932 (RSV
infection); cumulative five-year disease costs in the HPV model without immuni-
zation were 1,331,194 NIS. Total disease costs, with the programs (excluding the
cost of prophylaxis) were 3,305,522 NIS (PD) and 14,426,876 NIS (RSV disease), for
annual savings of 3,944,939 NIS and 3,562,056 NIS, respectively. HPV disease costs
over five years with the program were 535,480 NIS, saving an estimated 795,713 NIS
over five years. The immunization programs cost: 133,135,790 NIS (PD), 35,106,399
NIS (HPV) and 34,888,624 NIS (RSV disease). CONCLUSIONS: All programs had sub-
stantial acquisition costs, but annual net savings, when the costs of the program
were excluded. Even programs considered expensive are well-positioned finan-
cially within the context of other childhood preventive health strategies, when
targeted to appropriate populations.
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OBJECTIVES:A significant economic burden for society is linked to chronic obstruc-
tive lung diseases because of their high and still growing epidemiologic impact
worldwide. The purpose of this systematic review is to estimate the cost-of-illness
per case for the two most important obstructive lung diseases, asthma and COPD,
for adults in Germany.METHODS:A systematic search of Pubmed, Embase, EconLit
and Business Source Complete was performed for the years 1995 to 2012 in order to
identify German cost-of-illness studies for asthma and COPD. Studies identified
were analysed according to methods used, and cost findings were inflated to 2010
prices and compared within the same disease. RESULTS: Six studies for asthma,
seven for COPD and one for both diseases met the inclusion criteria. The costs for
asthma differ widely, ranging from minimum to maximum by a factor of 6.7 for
direct costs and 9.6 for indirect costs per case. For COPD, costs per case ranged by a
factor of 4.2 for direct costs and of 6.5 for indirect costs. In spite of the heterogeneity
in methodology and results, medication could be identified as the most important
single component of direct costs, and work loss as the most important component
of indirect costs. All in all, the estimated costs per case of illness and year varied by
a factor of 5.7 with a maximum slightly above 2,500 € for asthma and by a factor of
2.9 with a maximum of almost 3,500 € for COPD. CONCLUSIONS: Findings confirm
that asthma and COPD are costly but results vary markedly. COPD causes both
higher costs per case and higher total costs as a result of its higher prevalence.
Results emphasize the economic relevance of effective prevention and disease
management for these chronic obstructive lung diseases.
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CLINICAL AND PHARMACOECONOMIC ASPECTS OF ALLERGEN
IMMUNOTHERAPY IN THE SLOVAK REPUBLIC
Bielik J1, Pruzinec P2, Tor P3
1Trencin University, Trencin, Slovak Republic, 2University Hospital, Bratislava, Slovak Republic,
3Stallergenes CZ s.r.o., Bratislava, Slovak Republic
OBJECTIVES: To evaluate direct costs of allergen immunotherapy with regard to its
clinical benefit in the treatment of allergic rhinitis in the Slovak Republic.
METHODS: In co-operation with the General Health Insurance Company, the larg-
est insurer in Slovakia covering approximately 66% of all patients, the clinical
benefits were analyzed with respect to direct medical costs (cost of illness), costs
minimization and prevention of onset of asthma bronchiale (AB), in a short- and a
long-term period. The outcomes were obtained from an analysis of a group of
109,974 patients who were newly diagnosed with allergic rhinitis (AR) in 2002 and
were followed up until the end of 2010. In 2010, allergic rhinitis was detected in only
14,742 of these patients. RESULTS: The prevalence of AR and AB was 9.34% and
4.74%, respectively. In 2010, the total direct costs of AR and AB in Slovakia were
approx. 37,946,000 € and 51,512,000 €, respectively. Direct medical costs of AR and
AB treatment in 2010 in the evaluated group were 50.14 € and 198.03 €, respectively.
Allergen immunotherapy decreases average annual costs of pharmacotherapy of
AR by 17 € per patient and annual costs of prevention of onset of AB by 164.89 € per
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